GENE ONLINE|News &
Opinion
Blog

2018-11-22| PartnerAsia-Pacific

Med X Tech Summit Asia (MEDTEX) 2018 – Overview of Day 1 Program

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

Proudly co-organized by GeneOnline, the global biotech conference brings key opinion leaders comprising healthcare professionals and technology giants under one roof promoting scientific exchange and business partnerships. The event is to be held from Nov 29 – 30, 2018 at the Grande Luxe Banquet, Taipei, Taiwan.

This year, Taipei will bag the honor of hosting MEDTEX 2018, a showcase event displaying the digital revolution in the healthcare industry. This event is as an ideal opportunity to witness the latest advances in next generation bio-therapeutics and breakthroughs in precision medicine. MEDTEX will serve as the focal point where cutting-edge research and technology meet business perspectives. Expert talks will be delivered on various hot topics encompassing AIoT, Immune-Oncology, Blockchain, Big data, Gene editing and Cell therapy among others.

The following are some of the major highlights on the first day of the conference.

The guests will be welcomed with opening remarks from two honorary figures, Mr. Jia-Chyuan Su, President, Legislative Yuan (R.O.C) and Dr. Chi-Huey Wong, Distinguished Research Fellow at Academia Sinica.

1) The global healthcare industry is constantly evolving with the advent of new technologies and collaborative participation of many international players. Therefore, the inaugural program of the session is titled CEO Perspectives where a panel of distinguished speakers from various premier industries would discuss on the topic “Foreseeing the Future of Healthcare – Cross-industry Opportunities and Challenges of Healthcare Advances”. The goal is to garner key insights on cross-industry cooperation opportunities, challenges and strategies. The discussion will be moderated by Simon Chang, the Chairman of IBMI. The key members of the panel include Murakami Sei (Hitachi), Birgit Reitmaier (Merck), Larry Merizalde (Teva), Eunice Chiu (NVIDIA) and Harry Yang (Qisda).

2) The second panel discussion would focus on the new breakthroughs in the rapidly advancing fields of Immuno-oncology, Next generation Biotherapeutics and Gene editing. The discussion will be moderated by Clifford Chao, Vice President of the China Medical University. The speakers in the panel include Seigo Izumo (Takeda Pharma), Wise Young (StemCyte), David DiGiusto (Semma Therapeutics) and Tony J.C. Wang, (Columbia University Medical Center). The discussion also includes fireside chats from Trevor Martin (Mammoth Biosciences) and Chris Shu (Pacific 8 Ventures).

3) The final discussion session on the first day is titled Delivering Personalized Healthcare through Precision Medicine. The discussion will be moderated by Yun Yen, the Chair Professor of Taipei Medical University. The speakers in the panel include Alireza Haghighi (Harvard Medical School), Colin Collins (Vancouver Prostate Centre) and Liang-Yeu Lenny Chen (IBM Watson Health).

Interesting talks and discussions are also scheduled for the second day of the event. Follow GeneOnline for more details.

To register for the event, please visit

https://www.eventbrite.com/e/medtex-med-x-tech-summit-asia-2018-tickets-50897919046

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Merck Expands Hematology Portfolio With $1.35 Billion Imago Buy
2022-11-22
35% of Americans May Avoid Seeking Care Due to Concerns Over Healthcare Prices
2022-10-31
Merck’s Streptococcus pneumoniae Expansion Finally Receives European Commission Approval
2022-10-24
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!